UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (date of earliest event reported) – August 7, 2003
US Oncology, Inc.
(Exact Name of Registrant as Specified in Its Charter)
DELAWARE | 0-26190 | 84-1213501 | ||
(State or other jurisdiction of incorporation or organization) | Commission file number | (I.R.S. Employer Identification No.) |
16825 Northchase Drive, Suite 1300
Houston, Texas 77060
(Address of principal executive offices including zip code)
(832) 601-8766
(Registrant’s telephone number, including area code)
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
The following exhibits are furnished as part of this Current Report on Form 8-K:
Exhibit No. | Exhibit | |
99.1 | Press Release of US Oncology, Inc. dated August 7, 2003 |
ITEM 9. REGULATION FD DISCLOSURE
and
ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On August 7, 2003, US Oncology, Inc. issued a press release announcing its earnings for the second quarter of fiscal year 2003. A copy of the press release is furnished herewith as an exhibit.
The information furnished in this Current Report on Form 8-K, including the exhibit, shall not be deemed “filed” with the SEC and will not be incorporated by reference into any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 7, 2003
US ONCOLOGY, INC. | ||
By: | /s/ Phillip H. Watts | |
Name: Phillip H. Watts Title: Vice President - General Counsel |